Increased risk of second primary malignancy in thyroid cancer patients treated with radioactive iodine | J Natl Cancer Inst

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • This study found an increased risk of second primary malignancy (SPM) for thyroid cancer patients treated with radioactive iodine (RAI), especially with cumulative RAI doses over 150 mCi.

Key results

  • Among 20,235 patients with thyroid cancer, 692 cases of SPM were identified.
  • ...